A comprehensive view of novavax inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Novavax starting Phase 2b/3 Hummingbird global clinical trial of its COVID-19 vaccine in children aged six months to 11 years old; trial to enroll 3,600 kids in US, Mexico, Europe, South America, Asia, Africa, with results by Q1 2023

FDA gives emergency use authorization to Novavax’s COVID-19 vaccine for patients 18 years old and older in two-dose series; it’s hoped the more traditional protein-based vaccine will appeal to people hesitant about mRNA-based vaccines

SK Bioscience to manufacture commercial supply of Novavax’s COVID-19 vaccine containing Omicron variant in prefilled syringes; SK to begin manufacturing in 2023

FDA gives emergency use approval to Novavax’s protein-based COVID-19 vaccine, which is given in two doses, 21 days apart, giving US four vaccine options; about 200 million in US are fully vaccinated, tens of millions have received booster doses

US HHS secures 3.2 million doses of Novavax COVID-19 vaccine to offer another vaccine option this fall; FDA has not yet approved drug, although advisory panel endorsed the protein-based shot in June, which is given in two doses 21 days apart

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count